More importantly, we utilized the METTL3‐14‐WTAP activator to restore SETMAR expression and promote the differentiation of thyroid cancer, thus providing a new method of redifferentiation therapy for treating patients with thyroid cancer. The gene discussed is METTL3; the disease is thyroid gland carcinoma.